OPRX OptimizeRx Corp
Services-Business Services, NEC · Nasdaq · SEC CIK 1448431 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.0%
TTM net income YoY14,655.9%
TTM EPS YoY2,500.0%
Revenue 3-yr CAGR14.5%
Net income 3-yr CAGR—
Margins
Gross margin75.3%
Operating margin12.3%
Net margin5.3%
FCF margin21.1%
EBITDA margin16.8%
Returns
ROE3.9%
ROA3.0%
ROIC (approx.)5.5%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets17.4%
Debt / equity0.10x
Current ratio5.06x
Interest coverage3.12x
Cash quality & payout
Operating cash flow / net income3.98x
Accruals ratio-9.0%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $109.43M | $92.13M |
| Cost of revenue | $35.83M | $32.75M |
| Gross profit | $73.59M | $59.38M |
| R&D expense | $0 | $0 |
| Operating income | $11.69M | -$13.71M |
| Interest expense | $5.29M | $6.16M |
| Pretax income | $6.95M | -$19.39M |
| Income tax | $1.82M | $725,000 |
| Net income | $5.13M | -$20.11M |
| EBITDA | $16.02M | -$9.38M |
| EPS (basic) | 0.28 | -1.10 |
| EPS (diluted) | 0.27 | -1.10 |
| Weighted avg. shares (diluted) | 19.00M | 18.29M |
| Balance sheet | ||
| Cash & equivalents | $23.36M | $13.38M |
| Short-term investments | $0 | $0 |
| Receivables | $37.75M | $38.21M |
| Current assets | $64.72M | $53.97M |
| PP&E, net | $106,000 | $150,000 |
| Goodwill | $70.87M | $70.87M |
| Intangibles | $40.80M | $45.52M |
| Total assets | $176.92M | $171.17M |
| Current liabilities | $21.26M | $18.65M |
| Short-term debt | $4.25M | $2.00M |
| Long-term debt | $21.42M | $30.82M |
| Total debt | $25.68M | $32.82M |
| Total liabilities | $48.62M | $54.17M |
| Shareholders' equity | $128.29M | $117.00M |
| Net debt | $2.31M | $19.44M |
| Shares outstanding | 18.76M | 18.45M |
| Cash flow statement | ||
| Operating cash flow | $18.71M | $4.89M |
| Capital expenditure | $58,000 | $112,000 |
| Free cash flow | $18.66M | $4.78M |
| Investing cash flow | $68,000 | -$450,000 |
| Financing cash flow | -$8.80M | -$4.91M |
| Depreciation & amortization | $4.33M | $4.33M |
| Stock-based compensation | $6.96M | $11.47M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.